KLRS — Kalaris Therapeutics Share Price
0.000.00%
Last trade - 00:00- $109.04m
- -$9.25m
- 42
- 33
- 44
- 34
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.96 | ||
| Price to Tang. Book | 0.96 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -57.76% | ||
| Return on Equity | -45.37% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kalaris Therapeutics, Inc., formerly AlloVir, Inc., is a clinical-stage biopharmaceutical company engaged in the development and commercialization of treatments for prevalent retinal diseases. The Company is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Directors
- David Hallal CHM (54)
- Vikas Sinha PRE (57)
- Diana Brainard CEO (50)
- Ann Leen CFD (44)
- Brett Hagen CAO (48)
- Edward Miller GCN (56)
- Ercem Atillasoy OTH (56)
- Jeroen van Beek OTH (57)
- Juan Vera DRC (41)
- Jeffrey Bornstein IND (55)
- Malcolm Brenner IND (69)
- Ansbert Gadicke IND (63)
- Morana Jovan-Embiricos IND (54)
- John Wilson IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 19th, 2013
- Public Since
- July 30th, 2020
- No. of Shareholders
- 52
- No. of Employees
- 6
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 18,702,413
- Address
- 628 Middlefield Road, PALO ALTO, 94301
- Web
- https://kalaristx.com/
- Phone
- +1 6502492727
- Auditors
- Deloitte & Touche LLP
Upcoming Events for KLRS
Allovir Inc Annual Shareholders Meeting
Q2 2025 Allovir Inc Earnings Release
Similar to KLRS
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Kalaris Therapeutics share price?
As of Today at 21:31 UTC, shares in Kalaris Therapeutics are trading at $5.83. This share price information is delayed by 15 minutes.
How has the Kalaris Therapeutics share price performed this year?
Shares in Kalaris Therapeutics last closed at $5.83 and the price had moved by -68.57% over the past 365 days. In terms of relative price strength the Kalaris Therapeutics share price has underperformed the S&P500 Index by -71.66% over the past year.
What are the analyst and broker recommendations for Kalaris Therapeutics?
The overall consensus recommendation for Kalaris Therapeutics is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Kalaris Therapeutics dividend yield?
Kalaris Therapeutics does not currently pay a dividend.
Does Kalaris Therapeutics pay a dividend?
Kalaris Therapeutics does not currently pay a dividend.
When does Kalaris Therapeutics next pay dividends?
Kalaris Therapeutics does not currently pay a dividend.
How do I buy Kalaris Therapeutics shares?
To buy shares in Kalaris Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kalaris Therapeutics?
As of the previous close price of $5.83, shares in Kalaris Therapeutics had a market capitalisation of $109.04m.
Where are Kalaris Therapeutics shares listed?
Here are the trading details for Kalaris Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: KLRS
What kind of share is Kalaris Therapeutics?
Based on an overall assessment of its quality, value and momentum Kalaris Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kalaris Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Kalaris Therapeutics is $1.50. That is 74.27% below the last closing price of $5.83.
Analysts covering Kalaris Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.34 for the next financial year.
Find out moreWhat is the trend in the Kalaris Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kalaris Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -73.29%.
As of the last closing price of $5.83, shares in Kalaris Therapeutics were trading -55.86% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kalaris Therapeutics PE Ratio?
The Kalaris Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $5.83.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kalaris Therapeutics?
Kalaris Therapeutics' management team is headed by:
- David Hallal - CHM
- Vikas Sinha - PRE
- Diana Brainard - CEO
- Ann Leen - CFD
- Brett Hagen - CAO
- Edward Miller - GCN
- Ercem Atillasoy - OTH
- Jeroen van Beek - OTH
- Juan Vera - DRC
- Jeffrey Bornstein - IND
- Malcolm Brenner - IND
- Ansbert Gadicke - IND
- Morana Jovan-Embiricos - IND
- John Wilson - IND